Fig. 2

Tumorous IRE1α facilitates anti-tumor immunity in a CD8⁺T cells-dependent manner. A Schema of the treatment in C57BL/6 mice bearing B16F10 tumors received HA15 treatment as indicated. Tumor burdens, weights and volumes in each group were calculated and displayed in B and C. D Representative flow cytometry data and summary plots of the frequency of CD3⁺CD45⁺, CD8⁺CD3⁺, CD11c⁺CD45⁺, Foxp3⁺CD4⁺ and CD8⁺T-cells evaluated for expression of Granzyme B and IFN-γ in tumor from xenografts with indicated treatment. E Immunofluorescence staining of XBP1s or CD8α in B16F10 xenografts with or without the treatment of HA15. Scale bar, 50 μm. F-H Scheme representing the experimental procedure (F), tumor burdens, tumor weight (G), and tumor volume (H) of C57BL/6 mice injected subcutaneously with B16F10 tumors with treatment of HA15 and αCD8 depleting antibodies either alone or in combination. Symbols of one dot indicates one mouse, and the error bars are mean with ± SD (n = 4). Two-tailed Student’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant)